Rafferty Asset Management
FULC icon

Rafferty Asset Management’s Fulcrum Therapeutics FULC Stock Holding History

Rafferty Asset Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89.8K Buy
+24,538
New +$149K ﹤0.01% 1130
2024
Q4 		– Sell
-32,368
Closed -$116K – 1155
2024
Q3 		$116K Buy
+32,368
New +$240K ﹤0.01% 1125
2022
Q1 		– Sell
-12,971
Closed -$229K – 1257
2021
Q4 		$229K Buy
+12,971
New +$257K ﹤0.01% 1196

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rafferty Asset Management's FULC Position: Q2 2026 in Review

Rafferty Asset Management opened a new position in Fulcrum Therapeutics (FULC) in Q2 2026: 24,538 shares worth $89.8K. The stake represents ﹤0.01% of the portfolio and ranks #1130 among its holdings. This is a return to the name: Rafferty Asset Management previously reported a position in FULC as recently as Q3 2024.

Rafferty Asset Management first reported a position in FULC in Q4 2021 and has held it in 3 quarters since. The position peaked at $229K in Q4 2021. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Rafferty Asset Management held 24,538 shares of Fulcrum Therapeutics worth $89.8K as of Q2 2026.
  • Fulcrum Therapeutics was a new Rafferty Asset Management position in Q2 2026.
  • Fulcrum Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #1130 holding.
  • Rafferty Asset Management first reported a position in Fulcrum Therapeutics in Q4 2021 and has held it in 3 quarters since.
  • Rafferty Asset Management's Fulcrum Therapeutics position peaked at $229K in Q4 2021.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.